The choice of BE&K is based on their strong reputation and extensive experience serving advanced manufacturing businesses, especially within the biotech industry. We look forward to a productive partnership as we move forward with the first phase of our company’s facility expansion
THE WOODLANDS, Texas (PRWEB)
December 03, 2019
VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services company BE&K Building Group as Design-Build Partner for the initial phase of its new manufacturing site. The planned 240,000-square-foot facility will include expanded manufacturing capabilities and multiple flexible production suites to support both DNA and RNA-based biopharmaceuticals at all phases of development through commercial supply. Design of the first phase of the site is already underway, with projected completion of the initial facility within 2 to 3 years.
“The choice of BE&K is based on their strong reputation and extensive experience serving advanced manufacturing businesses, especially within the biotech industry,” stated VGXI CEO Young Park. “We look forward to a productive partnership as we move forward with the first phase of our company’s facility expansion.”
According to market reports, the gene therapy industry is rapidly gaining speed as recent approvals pave the way for a whole new class of medicines. A driving factor for both site selection and building design is available capacity to support VGXI’s continued, future expansions to meet growing industry demand. VGXI has identified and selected a suitable location for the construction project, with approval granted in November for a $1.2 million incentive during a special council meeting by the City of Conroe.
ABOUT VGXI, INC.
VGXI, Inc. is a leading provider of manufacturing and development services for DNA vaccines and gene therapies. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CDMO of GeneOne Life Science, Inc. To learn more or request a quote, visit http://www.vgxii.com.
ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) is an international DNA vaccine and product developer, and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines and products to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit http://www.genels.com/en.
ABOUT BE&K BUILDING GROUP
BE&K Building Group is an integrated construction services company serving pharmaceutical + biotechnology, advanced manufacturing + distribution, healthcare, and additional select commercial markets for more than 50 years. The company provides services nationwide through operations in Houston, Chicago, and the Carolinas. A full range of services is offered including construction management, design-build, preconstruction, programming + master planning, and client advisory + consulting. Additional information is available at http://www.bekbg.com.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.
